The use of botox armpits\u00a0was approved by the Food and Drug Administration in 2004 for patients whose hyperhidrosis is inadequately managed with topical agents.<\/span> The largest study reported to date was a \ufb01fty-two week, multicenter, double-blind, randomized, placebo controlled study involving 322 patients with axillary hyperhidrosis (Lowe et al. 2007). The proportion of treatment responders \u2013 those achieving a 2-point reduction on the<\/span> The median duration of effect of BOTOX treatment was approximately six and a half months. Furthermore, at \ufb01fty-two weeks posttreatment, it was estimated that at least 22% of BOTOX-treated patients had still not returned to having an HDSS score of 3 or 4 (which had been one of the study\u2019s key inclusion criteria). Patients whose HDSS scores did increase to this level were eligible for retreatment, and the duration of effect after such retreatment was similar to that after initial treatment, suggesting that ef\ufb01cacy does not <\/span>decline with repeat treatments.<\/span><\/p>\n Hyperhidrosis can result in considerable impairment in a patient\u2019s quality of life, and importantly, BOTOX treatment was also shown to result in signi\ufb01cantly greater improvements in this regard than<\/span> Other large studies in the literature,including one with even longer follow-up (sixteen months;Naumann et al. 2003), report similar \ufb01ndings and, in addition, signi\ufb01cantly greater patient satisfaction with BOTOX than placebo (Naumann and Lowe 2001).<\/span><\/p>\n
Prior to administering BOTOX<\/a>, many clinicians perform a Minor\u2019s starch iodine test to document the extentand severity of hyperhidrosis<\/a> in each axilla. This can then be used to mark the skin with a grid of evenly spaced injection sites . The approved dose of BOTOX<\/a> is 50 U1 per axilla, injected intradermally in 0.1- to 0.2-mL aliquots per injection site using a 30-gauge needle. In the pivotal trials, 100 U were diluted with 4.0 mL of nonpreserved saline. Discomfort with the axillary injections is min-<\/span>
imal, and the placing of ice packs on the axillae prior to treatment generally provides suf\ufb01cient anesthesia. Vibration and topical anesthetic creams have also been successfully employed to reduce pain.<\/span><\/p>\nBotox armpits reviews<\/h3>\n
Hyperhidrosis Disease Severity Scale (HDSS)2 \u2013 was signi\ufb01cantly greater four weeks after treatment with BOTOX 75 U or BOTOX 50 U than after treatment with placebo (75% and 75% versus 25%; p < 0.001).<\/span><\/p>\n
placebo. Furthermore, botox armpits injection appears to have an excellent safety pro\ufb01le.<\/span><\/p>\n